$637M to Power DeepIntent’s Next Chapter

Healthcare adtech platform DeepIntent has announced a $637 million investment from private equity firm Vitruvian Partners, marking one of the largest funding rounds in the healthcare media space to date. Vitruvian will acquire a majority stake in the company, with DeepIntent continuing to operate independently under founder and CEO Chris Paquette. 

When speaking with solli CEO Rich Springham, DeepIntent’s Chris Paquette emphasized that the partnership with Vitruvian is about more than capital—it’s about accelerating innovation in healthcare advertising. As he put it:

“At DeepIntent, our mission has always been rooted in improving patient outcomes by connecting life sciences companies, providers, and patients in smarter, more meaningful ways. With Vitruvian’s support, we’re accelerating the integration of generative AI and real-world data into our platform to give healthcare marketers the tools so they can deliver information with greater accuracy, relevance, and timeliness. This isn’t just about more efficient advertising; it’s about ensuring patients and providers have the knowledge they need to make better health decisions.”

Founded in 2016, DeepIntent has become a central player in connecting pharmaceutical and healthcare brands to patients and HCPs through data-driven advertising. The company’s platform integrates real clinical data, media decisioning, and AI-powered tools—supporting campaigns for 19 of the top 20 global life sciences companies. 

Why It Matters for...